MediWound (MDWD) Q1 2026 earnings review
A Bridge Quarter Plagued by Slipped Timelines
MediWound's Q1 2026 results reveal a company heavily constrained by manufacturing limits and external shocks. Revenue decelerated sharply to just $1.5M (down 63% YoY), pressured by delayed government contracts and regional conflict disrupting shipments. Simultaneously, operating losses hit $8.0M as R&D spending for the EscharEx trial surged. More concerning than the quarterly financials are the slipped operational timelines: the EscharEx Phase III interim assessment was delayed by a quarter, and critical EMA manufacturing facility approvals appear pushed back to late 2026. However, the award of a $197M BARDA contract to partner Vericel underpins management's reaffirmed $24-26M annual guidance, though this implies an aggressive, high-risk back-half revenue ramp.
🐂 Bull Case
The highly anticipated multi-year BARDA contract was awarded to partner Vericel (valued up to $197M). This secures long-term stockpiling revenue, development funding, and validates NexoBrid's strategic importance.
Despite a 63% collapse in revenue volume, gross margin actually improved to 21.9% from 18.7% YoY, suggesting favorable product mix and baseline unit economics remain intact.
🐻 Bear Case
The pivotal EscharEx Phase III VALUE trial is experiencing slower-than-expected enrollment. The critical interim sample size assessment is now delayed to Q1 2027 (previously guided for year-end 2026).
A recent EMA pre-audit identified modifications needed for the new manufacturing facility. Management now expects to implement these in H2 2026, threatening the previously guided H1 2026 EMA approval and delaying commercial capacity.
⚖️ Verdict: 🔴
Bearish. The long-term thesis relies on the EscharEx trial and expanded manufacturing capacity. Both saw material timeline delays this quarter. While the BARDA contract is a massive win, the execution risk required to hit the reaffirmed 2026 revenue guidance given current manufacturing constraints and regional geopolitical risks is uncomfortably high.
Key Themes
EscharEx VALUE Trial Pushed Back
In Q4 2025, management explicitly stated they were 'very comfortable' with a year-end 2026 completion for the EscharEx Phase III interim assessment. Just one quarter later, management acknowledged enrollment has progressed 'more gradually than originally anticipated,' pushing the interim assessment and enrollment completion to the end of Q1 2027. This deceleration is a critical red flag, as this trial is the company's primary long-term value driver.
Manufacturing Expansion Hits a Regulatory Snag
MediWound is currently capped by manufacturing capacity, with zero inventory and demand exceeding supply. The new facility (providing a 6x capacity increase) is vital. However, an EMA pre-audit identified necessary modifications. The company will not implement these until the second half of 2026, directly contradicting earlier guidance that expected EMA approval in H1 2026. This delay will severely constrain near-term product sales growth.
The $197M BARDA Anchor
The most significant positive development was Vericel securing the 10-year, $197M BARDA contract for NexoBrid. This covers procurement, vendor-managed inventory, blast-trauma indication development, and next-gen manufacturing. With initial procurement slated for H2 2026, this contract acts as the sole bridge to management achieving their $24-26M full-year revenue guidance.
Geopolitical Realities Hit Operations
For the first time, management explicitly cited 'postponed shipments related to regional conflict' as a material driver for the quarterly revenue miss. While previously stating they had ample clinical trial supplies, the inability to ship commercial product out of Israel introduces a severe, uncontrollable operational risk factor for H2 execution.
Unrivaled Industry Partnerships
Despite clinical delays, the commercial validation for EscharEx continues to grow. Medline joined the research collaboration for the clinical program this quarter. MediWound has now successfully aligned with virtually every major advanced wound care company (Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, B. Braun, MIMEDX, Medline), effectively standardizing care in their trials and building a massive funnel of potential future commercial partners.
Other KPIs
Accelerating burn rate. Cash used in operations more than doubled compared to the $4.1M used in 25Q1. This rapid cash consumption is driven by the scaling costs of the EscharEx trial and the $1.5M revenue shortfall. With $45M in total cash and equivalents remaining, the runway is sufficient, but margin for error is tightening.
Accelerating. R&D jumped 79% YoY from $2.9M. This is the primary driver of the widened $8.0M operating loss. As the VALUE trial adds more patients globally, this expense line will likely remain elevated until Q1 2027.
Guidance
Stable guidance, but requires extreme acceleration. Having delivered only $1.5M in Q1, the company must average roughly $8.0M per quarter for the rest of the year to hit the midpoint. Management confirmed this relies almost entirely on BARDA procurement beginning in the second half of 2026.
Key Questions
Manufacturing Timeline Clarity
With the EMA pre-audit requiring modifications that won't be implemented until H2 2026, when do you now expect final EMA and FDA approvals, and what revenue impact does this delay have on your 2026 and 2027 capacity?
EscharEx Enrollment Friction
You noted that enrollment for EscharEx progressed more gradually than anticipated. What specific bottlenecks are sites facing, and what 'targeted actions' have you implemented to ensure the new Q1 2027 target does not slip further?
Bridging the Revenue Gap
To hit the $24-26M guidance, you need significant revenue generation in Q2-Q4. How much of this remainder is guaranteed via the new BARDA contract versus reliant on unconstrained commercial product shipping?
Geopolitical Logistics Impact
Can you quantify the exact dollar amount of revenue that was postponed in Q1 due to the regional conflict, and have the logistical hurdles preventing those shipments been resolved for Q2?